Abstract 1937P
Background
To clarify the clinicopathological features and clinical outcomes of histological subtypes of papillary thyroid carcinoma (PTC) in the pediatric and adolescent population treated at a single institution.
Methods
A total of 153 PTC patients ≤18 years of age who underwent initial surgery between 1979 and 2019 were investigated. The most common subtypes included classic PTC in 124 (81%), solid variant in 16 (10%), diffuse sclerosing variant in 7 (5%), and follicular variant in 6 (4%). Cause-specific survival (CSS) and disease-free survival (DFS) rates were calculated by the Kaplan–Meier method.
Results
There were 135 female and 18 male patients, with a mean age at the time of surgery of 16 (range, 8-18) years, and 5% (8 patients) were ≤10 years of age at diagnosis. At initial surgery, 49 patients (32%) had lymph node metastases diagnosed preoperatively (cN1), 16 (10%) had gross extrathyroidal extension (ETE), and 18 (12%) had lung metastases. Total thyroidectomy was performed in 55 (36%) patients, and 98 (64%) patients underwent less than total thyroidectomy. During a mean follow-up of 16 years, 3 patients died of their disease, and 34 patients had recurrent disease. The 30-year CSS rate was 97.2%, and the 30-year DFS rate was 65.0%. On univariate analysis, extensive ETE (p=0.001) and cN1 (p=0.003), but not histological subtype (p=0.21), were associated with disease recurrence. Extensive ETE and cN1 were identified as significant factors related to DFS on multivariate analysis (hazard ratio (HR) 5.2, confidence interval (CI) 1.9-12.4, p=0.0028; HR 3.2, CI.6-6.6, p=0.0021).
Conclusions
The prognosis of pediatric patients with PTC was good, but recurrence was common. In pediatric PTC, histological subtype did not affect survival and recurrence.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18
1929P - Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Presenter: Laura Locati
Session: Poster session 18
1930P - Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Presenter: Jiaxin Niu
Session: Poster session 18
1931P - Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Presenter: Winston Wong
Session: Poster session 18
1932P - Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Presenter: Silvia Marchesi
Session: Poster session 18
1933P - Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Presenter: Raffaele Ciampi
Session: Poster session 18
1934P - Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study
Presenter: Yan Hu
Session: Poster session 18
1935P - Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Presenter: Sergio Pérez Fernandez
Session: Poster session 18